New Drug Application (NDA) for zuranolone in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) under priority review by U.S. Food and Drug Administration (FDA) with a PDUFA date of August 5, 2023
Sage and Biogen progressing key commercial preparations to support a potential launch of zuranolone in late 2023, following DEA scheduling period, if approved and expected timelines are met
Continued progress across pipeline with nine studies advancing across neuropsychiatry and neurology
Data demonstrating severe economic burden associated with depression presented at the Academy of Managed Care Pharmacy and The Professional Society for Health Economics and Outcomes Research
https://finance.yahoo.com/news/sage-therapeutics-announces-first-quarter-103000882.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.